Over the past several decades, asbestos has become vital in military environments, as this natural mineral was used extensively to construct barracks, vehicles, and other assets. Yet its widespread ...

The devastating long-term impact of asbestos exposure has once again been brought into sharp focus following the case of a ...

Mesothelioma is a rare but almost always fatal form of cancer linked to asbestos exposure. It is predominantly detected among ...

Pleural mesothelioma, specifically, is the most common type of mesothelioma, and it affects the mesothelial lining around the lungs. Why Are the Symptoms of Pleural Mesothelioma So Hard to Spot?

Malignant pleural mesothelioma molecular pathology, diagnosis, and treatment modalities are described in this article.

Dr. Hedy Kindler joins us on the podcast to discuss the latest update to the treatment of pleural mesothelioma guideline. She discusses the latest changes to the updated recommendations across topics ...

Keytruda plus chemotherapy is now a first-line treatment for pleural mesothelioma, replacing chemotherapy alone as the standard of care. The KEYNOTE-483 trial showed significant improvements in ...

Merck & Co. has won its first U.S. approval for use of its blockbuster cancer drug Keytruda in patients with malignant pleural mesothelioma, a rare cancer that grows in the membrane that lines the ...

The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

Lung cancer and pleural mesothelioma are often confused, so it’s important to understand the key differences between them, including tumor location and treatments.

Pleural mesothelioma (PM) is mainly caused by asbestos exposure and characterized by poor prognosis and limited therapeutic options. A recent research study identified the oncoprotein YB-1 as an ...

Pleural mesothelioma (PM) is mainly caused by asbestos exposure and characterized by poor prognosis and limited therapeutic options. A recent research study led by Karin Schelch and Michael Grusch ...